[ad_1]
Get a security check … working with health authorities around the world
AstraZeneca has decided to resume clinical trials of COVID-19 vaccine candidates in the UK.
AstraZeneca announced on the 12th (local time) that it will resume research in the UK, as the UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) confirmed that a clinical trial for the AZD1222 coronavirus vaccine is safe.
On Day 6, AstraZeneca voluntarily temporarily discontinued vaccines in all clinical trials worldwide so that safety data can be reviewed by independent international regulatory and committees in accordance with a standard review procedure, as a participant in one clinical trial reported serious adverse reactions. Arrested.
This time, the company said that the British Commission recommended to MHRA that it is safe to complete the investigation and resume clinical trials in the UK.
However, AstraZeneca and the University of Oxford said they could not release detailed medical information.
All researchers and clinical trial participants will receive relevant information, which will be published in the clinical trial registry system worldwide.
AstraZeneca emphasized that it is committed to maintaining the safety of clinical trial participants and the highest standards for conducting clinical trials.
He added that he will continue to work with health authorities around the world to be informed when other clinical trials can resume.
AstraZeneca is committed to providing a wide range of non-profit and fair vaccines during the coronavirus pandemic.
According to foreign media reports, the University of Oxford explained that in a large-scale clinical trial, some participants may be in poor health and that all cases must be carefully evaluated and safety tested.
So far, in vaccine clinical trials at AstraZeneca and Oxford, about 18,000 people are known to have received the vaccine.
AstraZeneca and Oxford are among the leading companies leading the way in developing a safe and effective corona vaccine.
Copyright © Medical News Unauthorized reproduction and redistribution prohibited
